Onxeo: Disclosure of Total Number of Voting Rights and Number of Shares in the Capital at October 31, 2014

PARIS--(BUSINESS WIRE)-- Regulatory News:

Onxeo (Paris:ONXEO) (NASDAQ OMX:ONXEO):

Pursuant to article L.233-8 II of the Code de commerce (the French Commercial
Code) and article 223-16 of the Règlement général de l’Autorité des Marchés
Financiers (Regulation of the French stock market authority):

Date Total number of outstanding shares Total number of voting rights
October 31, 2014 31, 490, 644 Theoretical number of voting rights: 31, 490, 644
(including treasury shares)

Number of real voting rights: 31, 469, 726
(without treasury shares)

About Onxeo
Onxeo has the vision to become a global leader and pioneer in oncology, with a
focus on orphan or rare cancers, through developing innovative therapeutic
alternatives to “make the difference”. The Onxeo teams are determined to develop
innovative medicines to provide patients with hope and significantly improve
their lives.

Key products at advanced development stage are:
Livatag® (Doxorubicin Transdrug™): Phase III in hepatocellular carcinoma
Validive® (Clonidine Lauriad®): Positive preliminary results of the Phase II
trial in severe oral mucositis
Beleodaq® (belinostat): registered in the US in peripheral T-cell lymphoma
For more information, visit the website www.onxeo.com
Onxeo
Judith Greciet, CEO
j.greciet@onxeo.com
+33 1 45 58 76 00
Nicolas Fellmann, CFO
n.fellmann@onxeo.com
+33 1 45 58 76 00
or
Alize RP
Caroline Carmagnol / Sophie Colin
caroline@alizerp.com / scolin@alizerp.com
+33 6 64 18 99 59 / +33 6 31 13 76 20